Guidance, NICE advice and quality standards In development
Showing 1 to 3 of 3
Title | Type | Expected publication date |
---|---|---|
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858] | Technology appraisal guidance | |
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056] | Technology appraisal guidance | |
Waldenstrom's macroglobulinaemia - ibrutinib [ID884] | Technology appraisal guidance |